UPDATE ON SYSTEMIC GLUCOCORTICOSTEROIDS IN DERMATOLOGY - 03/09/11
Résumé |
Since the initial description in 1951 by Sulzberger et al65 of the use of oral glucocorticosteroids (GCSs) for the treatment of skin diseases, these agents have been used for a wide variety of dermatologic conditions. The accompanying box includes a partial list of some of the conditions for which dermatologists most often prescribe systemic GCSs, although many other cutaneous conditions can be treated effectively with these medications. Since the 1950s, a variety of adverse reactions to GCSs have been noted, from the trivial to life-threatening and life altering. This article discusses basic GCS pharmacology, mechanisms of action, and treatment guidelines, with a particular focus on adverse effects and ways these effects may be minimized in clinical use.
• | Severe dermatitis
| ||||||||||||||||
• | Bullous dermatoses
| ||||||||||||||||
• | Vasculitis
| ||||||||||||||||
• | Collagen vascular diseases
| ||||||||||||||||
• | Neutrophilic dermatoses
| ||||||||||||||||
• | Miscellaneous dermatoses
|
Plan
Address reprint requests to Lee T. Nesbitt, Jr, MD, Department of Dermatology, LSU Health Sciences Center, 1542 Tulane Avenue, New Orleans, LA 70112 |
Vol 19 - N° 1
P. 63-77 - janvier 2001 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?